Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine

References

• GrüllichCImmunotherapy as modern tumor treatmentRadiologe2017571082282528871357
   PubMed Web of Science ®Google Scholar
• StewartBWildCPWorld Cancer Report 2014, International Agency for Research on CancerLyon CedexInternational Agency for Research on Cancer2014
   Google Scholar
• SlamonDJClarkGMHuman breats cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
   PubMed Web of Science ®Google Scholar
• StebbingJCopsonEO’ReillyHerceptin (Trastuzumab) in advanced breast cancerCancer Treat Rev200026428729010913383
   PubMed Web of Science ®Google Scholar
• ZamoranoJLLancellottiPRodriguez MuñozDESC Scientific Document Group2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)Eur Heart J201637362768280127567406
   PubMed Web of Science ®Google Scholar
• BowlesEJWellmanRFeigelsonHSPharmacovigilance Study TeamRisk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort studyJ Natl Cancer Inst2012104171293130522949432
   PubMedGoogle Scholar
• ChenJLongJBHurriaAOwusuCSteingartRMGrossCPIncidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancerJ Am Coll Cardiol201260242504251223158536
   PubMed Web of Science ®Google Scholar
• LimSLLamCSSegersVFBrutsaertDLDe KeulenaerGWCardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fractionEur Heart J201536312050206025911648
   PubMed Web of Science ®Google Scholar
• De KeulenaerGWDoggenKLemmensKThe vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapyCirc Res20101061354620056944
   PubMed Web of Science ®Google Scholar
• D’UvaGAharonovALauriolaMERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferationNat Cell Biol201517562763825848746
   PubMed Web of Science ®Google Scholar
• BersellKArabSHaringBKühnBNeuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injuryCell2009138225727019632177
   PubMed Web of Science ®Google Scholar
• TimolatiFOttDPentassugliaLNeuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytesJ Mol Cell Cardiol200641584585417005195
   PubMed Web of Science ®Google Scholar
• LuoMAndersonMEMechanisms of altered Ca2+ handling in heart failureCirc Res2013113669070823989713
   PubMed Web of Science ®Google Scholar
• BodenWEO’RourkeRATeoKKCOURAGE Trial Research GroupOptimal medical therapy with or without PCI for stable coronary diseaseN Engl J Med2007356151503151617387127
   PubMed Web of Science ®Google Scholar
• MargosPMargosNMokademNPatsiotisIKranidisARanolazine: safe and effective in a patient with hypertensive cardiomyopathy and multiple episodes of electrical stormClin Case Rep2017571170117528680620
   PubMed Web of Science ®Google Scholar
• SendónJLLeeSChengMLBen-YehudaOCARISA Study InvestigatorsEffects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine in Stable Angina (CARISA) randomized trialEur J Prev Cardiol20121995295922689417
   PubMed Web of Science ®Google Scholar
• AhmadSAhmadAHendry-HoferTBSarcoendoplasmic reticulum Ca(2+) ATPase. A critical target in chlorine inhalation-induced cardiotoxicityAm J Respir Cell Mol Biol201552449250225188881
   PubMed Web of Science ®Google Scholar
• TocchettiCGCarpiACoppolaCRanolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunctionEur J Heart Fail201416435836624464789
   PubMed Web of Science ®Google Scholar
• RiccioGAntonucciSCoppolaCRanolazine attenuates trastuzumab induced heart dysfunction by modulating ROS productionFront Physiol201893829467663
   PubMed Web of Science ®Google Scholar
• BaronJMBosterBLBarnettCMAdo-trastuzumab emtansine (TDM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancerJ Oncol Pharm Pract201521213214224682654
   PubMed Web of Science ®Google Scholar
• GaoJSwainSMPertuzumab for the treatment of breast cancer: a safety reviewExpert Opin Drug Saf201615685386326982349
   PubMed Web of Science ®Google Scholar
• FleemanNBagustABealeSPertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancerPharmaco-Economics20153311323
   Web of Science ®Google Scholar
• Van RamshorstMSvan WerkhovenEHonkoopAHDutch Breast Cancer Research Group (BOOG)Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: the TRAIN-2 studyBreast20162915315927498129
   PubMed Web of Science ®Google Scholar
• KropIEBeeramMModiSPhase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerJ Clin Oncol2010282698270420421541
   PubMed Web of Science ®Google Scholar
• RemillardSRebhunLIHowieGAAntimitotic activity of the potent tumor inhibitor maytansineScience1975189100210051241159
   PubMed Web of Science ®Google Scholar
• CassadyJMChanKKFlossHGRecent developments in the maytansinoid antitumor agentsChem Pharm Bull20045212614709862
   PubMed Web of Science ®Google Scholar
• WiddisonWCWilhelmSDCavanaghEESemisynthetic maytansine analogues for the targeted treatment of cancerJ Med Chem2006494392440816821799
   PubMed Web of Science ®Google Scholar
• FedeleCCarvalhoSRiccioGEffects of a human compact anti-ErbB2 antibody on gastric cancerGastric Cancer201417110711523460348
   PubMed Web of Science ®Google Scholar
• RiccioGEspositoGLeonciniECardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagentsFASEB J20092393171317819417081
   PubMed Web of Science ®Google Scholar
• Reagan-ShawSNihalMAhmadNDose translation from animal to human studies revisitedFASEB J20082265966117942826
   PubMed Web of Science ®Google Scholar
• SwainSMBaselgaJKimSBCLEOPATRA Study GroupPertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerN Eng J Med20153728724734
   PubMed Web of Science ®Google Scholar
• Amiri-KordestaniLWedamSZhangLFirst FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancerClin Cancer Res201420215359536425204553
   PubMed Web of Science ®Google Scholar
• SoyanoAEReynoldsGMoreno-AspitiaARifaximin for pertuzumab-related GI toxicitiesFront Oncol2017716828848707
   PubMed Web of Science ®Google Scholar
• MartínezMTPérez-FidalgoJAMartín-MartorellPTreatment of HER2 positive advanced breast cancer with TDM1: a review of the literatureCrit Rev Oncol Hematol2016979610626318092
   PubMed Web of Science ®Google Scholar
• FedeleCRiccioGCoppolaCComparison of preclinical cardiotoxic effects of different ErbB2 inhibitorsBreast Cancer Res Treat2012133251152121947749
   PubMed Web of Science ®Google Scholar